Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 2
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 3(1)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03337620Phase 3Completed

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

Role: collaborator

NCT04465357Phase 4Completed

Efficacy of Erenumab on Functional Impact of Migraine

Role: collaborator

NCT03108469Phase 2Completed

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

Role: collaborator

All 3 trials loaded